A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 251
- 试验地点
- 1
- 主要终点
- Change in MSSBP
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
详细描述
Essential Hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Patients with Essential Hypertension
- •Other inclusions applied
排除标准
- •Patient with Secondary Hypertension
- •Other exclusions applied
研究组 & 干预措施
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
干预措施: AD-227C (Drug)
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
干预措施: Placebo of AD-227B (Drug)
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
干预措施: AD-227A (Drug)
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
干预措施: AD-227B (Drug)
Co-administration of AD-227A and AD-227B
AD-227A + AD-227B + Placebo of AD-227C
干预措施: Placebo of AD-227C (Drug)
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
干预措施: AD-227A (Drug)
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
干预措施: Placebo of AD-227B (Drug)
AD-227A
AD-227A + Placebo of AD-227B + Placebo of AD-227C
干预措施: Placebo of AD-227C (Drug)
Co-administration of AD-227A and AD-227C
AD-227A + Placebo of AD-227B + AD-227C
干预措施: AD-227A (Drug)
结局指标
主要结局
Change in MSSBP
时间窗: Baseline to Week8
Change from Baseline in Mean Sitting Systolic Blood Pressure
次要结局
未报告次要终点